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1. Introduction to External Beam Radiotherapy
Soon after the discovery of x-rays in by Ro¨ntgen in 1895, the therapeutic
properties of radiation were being explored. Radiation was used initially as
a treatment for a number of non-cancerous and cancerous conditions. In
modern times radiotherapy has been used almost exclusively in the curative
and palliative treatment of cancer, often in combination with surgery and
chemotherapy.1 Radiotherapy may be divided into two principal categories:
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• Brachytherapy - the use of sealed and unsealed radioactive sources
placed near to or within the tumour requiring treatment;2,3
• External beam therapy (originally termed teletherapy) - the use of an
external beam of radiation, usually produced by a particle accelera-
tor4,5, 6 but also by radioactive sources.7,8, 9, 10
Teletherapy beams are provided either directly or from a source of sec-
ondary radiation; for example x-ray generation from electrons striking a
Bremsstrahlung target. Fast neutrons, or more exotic particles such as pions,
are also possible. In addition there are treatment involving two steps, such as
boron neutron-capture therapy (BNCT), in which epithermal neutrons are
absorbed by 10B nuclei which have chemically bound to tumour cells, giving
rise to alpha particle emission and hence a very local radiation dose.
The amount of energy deposited as radiation passes through a given depth
of tissue is referred to as the linear energy transfer (LET). X-rays and pro-
tons are considered to be low LET radiations, while other hadronic particle
beams such as neutrons and carbon ions are considered to have high LET.
The predominant type of external beam radiotherapy is x-ray therapy, where
a small (typically less than 2 metres) standing-wave or travelling-wave lin-
ear accelerator (linac) accelerates electrons to an energy of around 10 MeV
typically. When incident upon a transmission target these electrons produce
Bremsstrahlung radiation. This photon beam can then be collimated and
flattened to produce a uniform beam of defined field size. In the UK around
130,000 treatments a year are presently delivered involving 2.5 million atten-
dances, more than half of which are for breast and prostate treatment.11
Although the linacs used for x-ray therapy are both relatively compact
and produced in large numbers, and therefore relatively inexpensive com-
pared to proton and other ion accelerators, the resultant radiation dose de-
livered by the photons within the patient is not ideal. Whilst photons give a
low surface dose - providing valuable skin sparing - this dose rises rapidly to a
maximum within the first ≈2.5 cm of tissue before falling with depth due to
attenuation and the inverse-square law. A single beam direction will there-
fore deliver lower dose at the depth of the tumour than it does to healthy
tissue upstream and will unnecessarily irradiate healthy tissue downstream
the tumour. These inherent limitations may be partly overcome to give bet-
ter conformation to the tumour of the delivered dose by:
• Bringing beams onto the target volume from a number of directions;
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• Defining the transverse shape each beam using a multi-leaf collimator
(MLC);
• Varying the intensity of each beam through the technique known as
intensity-modulated radiation therapy (IMRT).
Through these means modern x-ray radiotherapy can provide good con-
formation of the high-dose volume to the target, but inherent in the treat-
ment is the irradiation of large amounts of healthy tissue with medium and
low doses. Good treatment planning seeks to optimise this tradeoff and to
minimise dose to sensitive structures.12,13,14,15,16 There are presently around
265 linacs in clinical use in the UK and a funded programme to dramatically
expand the use of IMRT.11 Three-dimensional computed tomography (CT)
provides sufficient resolution of the electron density to x-rays17,18,19 given
that the depth-dose curve for x-ray absorption is rather smooth. This is
supported by magnetic resonance imaging (MRI) to improve targeting, par-
ticularly in soft tissues. Computer-aided optimisation of the treatment dose
is used with a number of irradiation fields to spare tissues and organs at risk
that are near to the tumour.12,20,13,21,5, 22, 23
2. Particle Therapy
In contrast to x-ray therapy, radiotherapy with charged hadronic species
such as protons feature a depth-dose curve that concentrates the dose around
the Bragg peak, a characteristic of the Bethe-Bloch energy loss for these par-
ticles.24,25,26,27,28 The depth at which the peak occurs increases with particle
energy; for incident protons above 70 MeV an approximate rule of thumb is
that protons lose around 1 MeV per millimetre of water traversed, although
this reduces with increasing incident energy. The range of a 230 MeV pro-
ton is roughly 33 cm in water, so that this energy is sufficient to be used
for tumour treatment in a typical adult patient. For a given depth of the
Bragg peak, heavier particle species such as carbon ions require greater en-
ergy; for example, to treat to a depth of 33 cm would require a C 6+ ion
of 400 MeV/nucleon. Both accelerators and beam delivery systems to the
patient must cope with the significantly greater beam rigidity if carbon ions
are used (see later), leading to greater magnetic bending and focusing fields
and thus larger accelerators.
With efficient ion sources and compact accelerators, protons are the most
accessible of hadronic beams and deliver tangible benefits over photons when
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traded-offs against accelerator size and cost.24 However, heavier ions have
the distinct advantages of greater radio-biological effectiveness (RBE) and
smaller lateral scattering; carbon ions in particular have been used for patient
treatment for this reason.29
The sharp peak in the hadron depth-dose curve means that accurate imag-
ing and planning are very important; a 1 cm range error in x-ray radiotherapy
will change the dose to the tumour or normal tissue by approximately 2 %
along the beam path, whereas a 1 cm range error in hadron therapy will shift
the distal edge of the dose distribution and may thereby give a much larger
change to the dose delivered at a particular location.
Whilst CT provides sufficient tissue density information for planning x-
ray treatments, the conversion of Hounsfield numbers to tissue density is
not accurate enough to provide optimal proton planning.24 Hence there is
significant interest in improving existing imaging techniques with, for ex-
ample, a number of researchers developing proton computed tomography
(PCT)30,31,32,33 and positron emission tomography (PET)-based dose moni-
toring, the latter utilising the 11C and 15O generated during proton or carbon
irradiation.34
In order to provide PCT, particularly in adult patients, the proton energy
must be larger than that required for treatment; protons exit the patient with
a residual energy which is measured and - by comparison with the already-
known entrance energy - used to determine the integral of the patient tissue
density along the line between entrance and exit.35,32 Tomographic recon-
struction from many such tracks is undertaken in the same manner to other
imaging techniques, but since the density determined here is proton-specific
it may be translated directly into a required proton energy for treatment.
This method may thereby reduce range error if the proton energy can be
measured accurately enough.
As well as photons, protons and carbon ions, radiotherapy has also utilised
other particle species. Very high-energy electron therapy (VHEET) uses an
electron beam (of energy up to 250 MeV) directly rather than using it to
create x-rays;36,37 at sufficiently large energies there is believed to be a ther-
apeutic benefit compared to photons, but compact facilities require larger ac-
celerating field gradients than are yet commercially available. Fast neutrons
were used in clinical studies during the 1960s and 1970s but poor dose local-
isation overshadowed the high-LET benefits.38,39,40,41 Finally, exotic species
such as pions and antiprotons are also candidates for radiation therapy. The
potential advantage of these latter two species is the additional energy pro-
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duced from the nuclear absorption of the stopped particles, adding to the
energy released at the Bragg peak depth; this is referred to as a star dose.42
The use of antiprotons has also been studied, particularly at the Antipro-
ton Cell Experiment (ACE) at CERN;43 the proposed advantages are the
RBE enhancement adjacent to the Bragg peak from the antiproton annihi-
lation, and the possibility of using the pions generated for dose monitoring.
Recent studies confirm such an RBE enhancement, but at present there is
disagreement about the acceptability of the longer-range halo dose.44,45,46
Held out as a great hope for treatment of glioblastoma, boron neutron-
capture therapy (BNCT) is a combined technique in which epithermal neu-
trons (from a suitable reactor or accelerator-based source) are shaped in
energy by a moderator assembly to optimise their spectrum to be absorbed
by 10B nuclei bound chemically to (possibly dispersed) tumour cells, giv-
ing rise to alpha particle emission and hence a (very) local radiation dose.47
The main challenges for BNCT use are the availability of a compact, high-
flux neutron source, the subsequent shaping of the source spectrum to avoid
neutron irradiation that can cause very substantial damage to tissue outside
the tumour region and the development of suitable boron compounds that
can penetrate the blood-brain barrier and bind to tumour cells.48,49 Present
BNCT facilities utilise either a neutron source derived via a graphite column
from a nuclear reactor, or moderate the fast, broad-spectrum neutron out-
put from a thick lithium or beryllium target struck by protons with energies
typically between 2 and 30 MeV.50
3. History of Particle Therapy
Following Robert Wilson’s suggestion of using protons for radiation ther-
apy,51 experimentation was started using the 184-inch synchrocyclotron at
Lawrence Berkeley Laboratory;52,53 the first patients were treated in 1952,
but not with stopped beams.54 At that time diagnostic devices were not
available to provide adequate tissue-density information to determine the
correct beam energy for the protons to stop in the tumour; this level of
sophistication did not emerge until CT scanning became available in the
1970s. The earliest treatments used plateau irradiation, in which the full en-
ergy beam of up to 900 MeV was collimated and passed through the target
volume. Incident beams were delivered to the patient at a variety of angles,
overlapping the delivered fields to concentrate the dose at the desired loca-
tion.55,56 Target volumes were small (for example at the pituitary gland)
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and ablation studies for treatment of endocrine-related diseases (Cushings
acromegaly) were highly successful. Over 2000 patients were treated by this
technique in Berkeley. Russian programmes at ITEP and at St. Petersburg
Nuclear Physics Institute/CRIRR were also quite successful.57,58,59,60 Fol-
lowing experiments initiated at NIRS (Chiba) and at Tsukuba at the end
of the 1970s,61,62 Japan has become one of the world’s largest users of both
proton and heavy ion therapy.63
Stopped-beam treatments with protons (i.e. utilising the concentrated
energy loss at the Bragg peak depth) were started at the Gustav Werner In-
stitute in Uppsala (Sweden) and at the 160 MeV Harvard Cyclotron (USA)
in the early 1970s,55,64,65 although stopped helium ions had been used a few
years earlier.54 Heavier ions were pioneered at the Berkeley accelerators, the
184-inch synchrocyclotron producing helium beams and the Bevalac gener-
ating therapeutic beams from carbon to argon. Over 2000 patients were
treated with these heavier ions, with the majority of Bevalac patients (close
to 500) receiving treatments with neon ions.
The first dedicated hospital facility was developed at Loma Linda using
a Fermilab-designed 250 MeV synchrotron and opened in 1990.66,67,68,65 A
synchrotron was chosen as it was considered that a synchrotron could pro-
vide the rapid energy variation and dose rate control required for accurate
patient treatment. Subsequently cyclotrons, synchrotrons and latterly other
technologies were developed for proton therapy, initially at accelerator labo-
ratories and then commercialised by a number of providers.65,64 The Loma
Linda facility pioneered the delivery of a single source beam to more than
one treatment room, enabling multiple patient treatment, although not si-
multaneously due to the time required to switch from one room to another.
Loma Linda also demonstrated the clinical use of rotating gantry systems
that deliver protons into a patient from a number of directions, which avoids
the need to rotate the patient other than in the horizontal plane, whilst
essentially still providing treatment beams from any angle.
Extensive trials with pion beams were conducted at Paul Scherrer Insti-
tute (PSI), TRIUMF and LAMPF in the 1970s, of which the most creative
beam delivery concept was developed at PSI; called the Pion Concentrator
(or Piotron),69 the production target was struck with 590 MeV protons with
60 channels fanning out in a cone from the optimum production angle of
about 60 ◦. These channels transported purified and energy-selected pions
and brought the beamlets to an image point of the target at the site of the
patient; a sufficient dose rate of pions could be achieved so that a daily frac-
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tion could be delivered in a few minutes. Several thousand patients were
treated with pions at these facilities;70,71,72,73 clinical results were unsatisfac-
tory, in part due to the relatively poor dose localisation from greater multiple
scattering of the pions compared to the substantially heavier protons. There
have been studies of more cost-effective pion sources, such as PIGMI.74
Heavy ions for therapy first became available in the early 1970s at the
Princeton-Pennsylvania Accelerator75,76 and at the Bevalac in Berkeley,77
with measurements of the stopping profile and biological effects being made
quickly.78,79 Being more massive than protons, heavy ions such as carbon,
oxygen, nitrogen and neon will scatter less and thereby provide a sharper
edge to the imparted radiation field.80 In addition LET is significantly higher
than for protons. However, a significant proportion of the ions may undergo
nuclear reactions that produce lighter fragments that can travel beyond the
primary Bragg depth; this tail dose is significant when treating at depths
greater than 20 cm. More recent facilities in Japan, Germany and Italy have
opted for carbon ions, mainly because of the less damaging plateau dose and
RBE enhancement near the Bragg peak, but also because of the reduced
fragmentation and more manageable accelerator size.
4. Particle Sources
At present, nearly all hospital or laboratory centres use either a cyclotron
or synchrotron as a particle source of either protons or carbon ions,81,82,83
delivering treatment beams to either single treatment rooms or (more fre-
quently) multiple treatment rooms; in the latter case a transfer line and
switching magnets are required to select which room receives beam. Both
cyclotrons and synchrotrons are mature technologies with well-established
routes for delivering maximum proton energies in the 200-350 MeV range or
even higher.84,85 At present, carbon ions at clinically useful energies are only
provided using synchrotrons, although several cyclotron- and linac-based de-
velopments are underway.
Many alternative technologies are in active development; these include
linacs, hybrids of linacs with circular machines,86 new techniques involving
induction acceleration (e.g. dielectric wall accelerators), laser-generated pro-
ton beams,87,88 or novel forms of conventional accelerators such as fixed-field
alternating gradient (FFAG) rings.89,90,91 Those technologies in or close to
clinical implementation are described below, whilst some others of interest
are discussed in Section 7.
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4.1. Normal-Conducting Cyclotrons and Synchrocyclotrons
The normal-conducting cyclotron was the first circular (and therefore
cyclic) accelerator to be used, following its invention by Ernest Lawrence in
the 1930s.92,93,94 There are a number of variants, which include techniques to
keep the driving radio frequency acceleration in synchronism with the orbit
period.95,96,97 Synchronism is achieved either by modifying the pole shapes
to make the orbits isochronous, or by varying (in the synchrocyclotron) the
RF frequency during an acceleration pulse. Virtually all hospital-based ther-
apy cyclotrons utilise the first approach and at present deliver a maximum
proton energy of 235 MeV, but several commercial vendors have proposed or
are constructing synchrocyclotrons. Higher energies have been achieved in
research machines such as the 590 MeV PSI cyclotron,98 but cyclotrons of this
energy have not yet been commissioned outside of accelerator laboratories.
To allow for depth scanning of the tumour, some method must be em-
ployed to vary the proton beam distal (maximum) depth, since the output
energy from a cyclotron is to all intents fixed. To achieve this variation in
incident proton energy, the beam from the cyclotron is passed through an
adjustable thickness of some material, typically two back-to-back wedges of
carbon. The mean energy loss is accompanied by an increase in energy spread
and beam emittance due to scattering, so the output beam must be cleaned
in an energy-selection system prior to the final beam delivery system. En-
ergy selection is achieved with a combination of dipole magnets, collimators
and extensive shielding to select the energy and emittance of the beam that
can be transported through the gantry to the patient. Typically cyclotrons
can deliver sufficient beam intensity so that despite the beam loss from the
energy selection process (by as much as a factor of one hundred or more for
the lowest energies), they provide a dose rate that is competitive with other
accelerator types. It is also worth noting that in typical cyclotron designs the
output spot is basically circular, which simplifies the beam coupling to the
final beam delivery system, for example to a downstream rotating gantry.
4.2. Superconducting Cyclotrons and Synchrocyclotrons
The higher fields (above about 3 T) which are available from supercon-
ducting magnets allow higher extraction energies at a particular orbit ra-
dius;99,100,101,102,103 this allows cyclotrons to be made smaller for a given
extraction energy but with the penalty of the greater capital cost of the mag-
net and operating cost of the cryosystem.84,104 Reliability is not necessarily
worse with a low-temperature rather than a room-temperature magnet, as in
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practice reliability is often determined by other points of failure. However,
maintenance work on the accelerator will usually include a significant time
overhead from warm-up and cool-down of cryogenically-cooled components.
Several commercial vendors are now either developing or offering super-
conducting cyclotrons;103 Mevion utilise NbSn3 superconducting magnet coils
that allow the cyclotron to be small enough to be gantry mounted whilst
maintaining a maximum proton energy of around 250 MeV. Varian-ACCEL
use NbTi to have a larger, lower-field and therefore simpler magnet to obtain
250 MeV protons at extraction,105 whilst IBA also use NbTi in their 230-
250 MeV S2C2 cyclotron.104 Superconducting magnets are often less than
half the weight of their normal-conducting equivalent.25 There is a research
and commercial push to develop cyclotrons with higher extraction energies,
but as yet no commercial solution has been installed to our knowledge.
4.3. Radiofrequency Linacs and Cyclinacs
Proton linacs for radiotherapy have been proposed, using either a con-
ventional pre-injector or using a low-energy cyclotron as the proton source
(so-called cyclinacs). Accelerating structure developments have been made
towards the goal of having sufficient accelerating gradient for them to be used
in a hospital context, particularly at S-band (3 GHz) frequency; two Italian
collaborations - TERA106,107,108 and TOP-IMPLART109 - have separately
developed 3 GHz structures,110 whilst other groups have studied upgrades of
existing cyclotrons.111 The frequency mismatch between the cyclotron and
linac can result in significant beam loss in the first cells of the linac, but the
higher current available at low energy compensates for this. This technique
has also been pursued for carbon-ion therapy112 with structure development
underway.113,114 Low-energy sections for proposed facilities have been con-
structed in Italy and clinical facilities are either planned or proposed here
and elsewhere. The TERA TULIP design proposes combining the accelerat-
ing structures and rotating gantry to provide a single-room solution.115 The
same structure development has also been recently proposed by Advanced
Oncotherapy to provide a linac-based proton therapy centre,116 although no
centres are yet operating using this scheme.
4.4. Synchrotrons
Synchrotrons are a well-established technology in proton therapy and
there have been numerous slow-cycling (up to a few hertz) examples used
clinically.66,67,65,117,118,119,120,121,122,123 At present, synchrotrons are the only
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accelerator technology used to provide carbon ion beams. All current de-
signs follow the original approach by GSI and implemented at Heidelberg,122
which uses: an ECR ion source, a radio-frequency quadrupole and drift-tube
linac, and finally a synchrotron to accelerate carbon ions up to 400 MeV per
nucleon.124,125,126 Energy variation of the proton or carbon beam distal (max-
imum) energy is accomplished by extracting the beam at different times in
the acceleration cycle. Extraction is commonly achieved using either a third-
order resonance or RF-knockout scheme and a feedback system is employed
to ensure that the extracted dose can be controlled to provide both good dose
stability and beam intensity that is programmable in time. Furthermore, ex-
traction can be gated to synchronise the dose with the patient’s breathing, in
order to minimise the effect of organ motion. In comparison with isochronous
cyclotrons, where particles are continuously injected and accelerated, in syn-
chrotrons (and similarly in synchrocyclotrons) the injection window is short,
so the number of particles available at treatment energies is substantially
lower. Nonetheless, dose rates are still adequate and in a synchrotron the
available particle flux at each extraction energy is essentially constant; this is
in contrast to cyclotrons, where the the extracted beam intensity is reduced
by up to three orders of magnitude by the scatterers used to reduce the mean
particle energy.
4.5. Rapid-Cycling Synchrotrons
Brookhaven National Laboratory (BNL) in conjunction with a commer-
cial company (BEST)127 have spearheaded the idea of a rapid-cycling syn-
chrotron for either proton or carbon-ion therapy, although other groups have
also initiated designs.128 BNL propose that a maximum cycling frequency of
30 Hz allows the use of simpler magnets and resonant power supplies and in
principle a pulse-by-pulse energy variation at the cycling frequency is pos-
sible by timing the firing of the extraction kicker during the acceleration
phase.129,130 Slow extraction is not possible and intensity feedback is both
required and difficult; intensity control must be done either by trimming
during acceleration, or by exquisitely fine control over the injected current.
5. Facility Layout Options
A single accelerator can provide a particle beam to a single treatment
room or to multiple treatment rooms; some rooms may then have gantries to
translate the horizontal beam entering the treatment room into the vertical
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plane, with the patient either stationary with the gantry rotating around
them (isocentric) or with some combination of patient and gantry motion.
The rationale for gantries, and their design issues, are discussed below. The
combination of a rotating gantry with a patient table that rotates in the
horizontal plane allows the particle beam to enter the patient from any angle,
in contrast to treatment with a fixed beam orientation. A third option is to
mount the accelerator on the gantry, which is only possible if the accelerator
is small and light enough that the resulting gantry is of reasonable size; of
course in this scenario the accelerator can only support one treatment room.
In most proton and carbon-ion systems today the particle source is not
mounted on the gantry, but instead is located in a separate, static location.
The advantage of having several treatment rooms supplied by a single ac-
celerator is that patients can be prepared for treatment in parallel prior to
irradiation, thus making optimal use of the available accelerator time. The
gantry beam-optics system must couple to the source, and beam switching is
ideally fast so that the beam is ready for initiation of treatment within a short
time (typically less than one minute) from the operator’s request. The dis-
advantages of a single accelerator/multi-room arrangement are the reduction
in flexibility and the complication of parallel patient scheduling, although
the optimisation of throughput planning is becoming more advanced. Monte
Carlo modelling studies suggest three to four treatment rooms per acceler-
ator provides optimal utilisation of all resources.131,132,133 In a multi-room,
single-accelerator facility there is the risk of the accelerator source being the
single point of failure for all treatment rooms, which must be taken into
account. Reliability (measured as the fraction of time available over that de-
manded) of the accelerator systems of at least 98 % is typically required.134
Such facilities may be upgraded by modifying or replacing the accelerator
whilst leaving the treatment rooms as they were; this modification has been
performed at the PSI proton therapy centre where a dedicated cyclotron was
added to an existing treatment room suite.135
Whilst the shielding requirements in all proton or carbon-ion facilities
are naturally significant, particular attention must be paid in cyclotron-based
facilities to the relatively larger amount of activation arising from the energy-
selection system. Conversely, coupling cyclotron and linac beam optics to
gantry optics is relatively simpler due to the circular beam spot. This is in
contrast to synchrotrons where the spot may be significantly asymmetrical;
this requires rather special measures to match the accelerator and gantry
beam optics.136
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If the particle source can be made small enough the option exists to
mount it directly on the treatment gantry. Since the accelerator is directly
mounted on the gantry, the beam optics are much simpler but the gantry as a
whole may not be smaller or lighter, depending on the source used (typically
a compact cyclotron,137,138 but potentially a dielectric wall accelerator or
laser-based acceleration scheme, see below). The issues of parallel treatment
and scheduling are greatly simplified or eliminated and if there are a number
of treatment rooms each with its own gantry and source then there is no
beam-derived single point of failure. Beam clean-up and elimination of the
parasitic neutron dose will however be more complex as they must be done
close to the patient. Whilst some studies indicate that this could be manage-
able, the issue is still a the subject of research.139 Presently, only compact
superconducting synchrocyclotrons can deliver 250 MeV protons whilst at
the same time being small enough for the gantry and treatment room to be
practicable.
6. Beam Delivery and Field Formation
It is of course not enough to merely bring a hadron beam into a treatment
room; its distribution transversely and longitudinally must be capable of be-
ing conformed to the tumour volume in (x, y, z) according to a predetermined
treatment plan. Prior to the operation of the Loma Linda facility, treatments
were carried out using both fixed beamlines and fixed patient orientation.
Flexibility in the entry orientation of the beam is important, and whilst
static horizontal delivery is still preferred for some fields (such as ocular
treatments) the capacity to provide an arbitrary entry angle, via a gantry,
is highly favoured by the medical community.140 The use of gantries and
the related issues of field shaping and dose conformation and how they are
achieved using passive or active methods are discussed below.
6.1. The Use of Gantries
As well as the requirement to spread the dose throughout the volume of
the tumour, it is of course desirable to direct treatment beams with the least
possible impact on organs or other tissues that are either in close proximity
to the treatment volume or which lie between the treatment volume and
the patient’s external surface. To achieve this goal, it is necessary to either
rotate the patient or rotate the beam line that is delivering the particles
to the patient. Although it is acceptable to rotate or translate a supine
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patient in the horizontal plane, full six-dimensional patient motion is not
possible.140 This is primarily due to the undesirable organ motion relative
to the external body reference points used to align the treatment beam;
thus horizontal rotation is acceptable but not other axes. Rotation may
also be difficult for the patient, or interfere with other medical procedures
such as anaesthesia. Some treatments are suitable for use with fixed angle
beam (which may be horizontal, vertical or something in between), with the
patient either supine, prone or sitting up; a notable example is the treatment
of ocular tumours where the patient is seated and the incident particle beam
fixed and horizontal. However, to provide maximum flexibility the concept
of the rotating delivery beam line (gantry) has been developed, mimicking
the situation in x-ray radiotherapy where the gantry rotates 360 ◦ around a
patient lying on a couch, with the couch’s default position along the axis of
gantry rotation. If the patient couch is allowed to rotate in the horizontal
plane, a more compact treatment room is possible as the gantry is only
required to rotate 180 ◦ (from vertically-down to vertically-up).
There are several reasons to keep the patient supine during radiotherapy
treatment:
• To more easily reproduce the patient position used for pre-treatment
imaging such as CT that has been used for treatment planning;
• To more easily reproduce the patient position through several weeks of
daily treatment;
• To maximise the flexibility in possible beam directions to avoid normal
tissue and therefore to target the tumour most effectively.
In external beam radiotherapy by far the most common method is for the
patient to lie on a treatment couch, imitating the position used for CT scan-
ning. When accompanied with sensible immobilisation devices, this ensures
organs are in similar position during both treatment planning and treatment,
to give a reproducible set up. To maximise the number of possible treatment
angles the couch can have up to five degrees of freedom, with tilts of the
couch limited to less than 5 ◦ for patient comfort.
6.2. Gantry Design
Conventionally, the term gantry is used to refer to a particle beam trans-
port line that is designed to rotate around an axis; a gantry consists of a
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mechanical support structure, drive mechanism, magnets, vacuum vessels
and beam diagnostics, along with other secondary technical infrastructure.
The de-facto standard gantry design that has emerged is the isocentric ap-
proach, wherein the patient is kept essentially still in a prone position with
the centre of rotation of the gantry passing in the horizontal plane through
the patient and the incident beam rotated in the vertical plane around the
patient. A number of dipoles are used to transport the beam from the par-
ticle source to the treatment room which it enters along this axis. Further
dipoles on the gantry are used to create an offset between the beam and the
gantry rotation axis and finally turn the beam toward the patient who is
positioned at the isocentre. Quadrupoles are used to provide beam focusing
both in the beam transport prior to, and within, the gantry. The isocentric
approach is shown schematically in Fig. 1.
Accelerator plane
(horizontal)
Gantry plane rotation
Gantry plane
(rotating)
Isocentre
Transfer line
Accelerator source
Coupling point
Figure 1: A schematic illustration of a particle therapy installation incorporating an isocen-
tric particle therapy gantry. The gantry plane rotates around an axis that is horizontal
and passes through the isocentre within the patient.
The components between the final bending magnet and the exit window
to the patient are sometimes referred to as the treatment nozzle. As well
as beam position and dose monitors it may include deflection magnets to
scan the spot transversely, or alternatively beam scatterers and collimators
to spread and shape the proton dose across a chosen field size; these field
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sizes may now be as large as 30 × 40 cm. The need for a treatment nozzle
will always require a distance of several metres between the last bending
magnet of a gantry and the patient. To obtain a full 4pi coverage of the
patient, the gantry must rotate at least 180 ◦ in conjunction with a patient
table that rotates 360 ◦ in the horizontal plane. To minimise patient rotation
(which introduces time delay and may result in unacceptably large patient
misalignment) many gantry designs utilise the full 360 ◦ of rotation around
the patient.
Isocentric gantry designs typically incorporate either two or three dipoles
as illustrated in Fig. 2 (but may incorporate more126,141) and are designed
to minimise the total mass of the gantry magnets whilst also minimising the
outer radius and length of the entire rotating structure. Despite this, gantries
still involve a large mass of magnet steel and a mechanical structure that is
many metres in both length and radius that rotates around the patient; most
of this assembly is typically disguised behind a false wall and therefore not
visible to the patient in the treatment room. Gantry-mounted sources such
as compact cyclotrons do not require the same number of beam steering
elements, since the particles from the cyclotron may be directed straight at
the patient; however there is then less space to incorporate beam cleaning
and scanning elements.
Alternative approaches to the isocentric concept have been proposed to
reduce the mass of moving steel. The most notable of these is the so-called
“Riesenrad” (or ferris wheel) gantry, wherein a smaller number of deflecting
magnets lie on the gantry rotation axis and the patient displaced from that
axis; if the gantry and patient are rotated (but the patient kept supine)
the patient will receive the dose from different angles.142,143 The Riesenrad
gantry is shown schematically in Fig. 3. Such gantries have less moving steel
and are therefore lighter, but have more complex patient-handling issues
compared to isocentric gantry installations; the principal of these is that
patient entry and egress are more time-consuming, which may be an issue
during emergencies.
A hybrid scheme (often referred to as an eccentric gantry) has been im-
plemented at PSI (at Gantry 1), in which both the patient and the beam
line magnets move around the rotation axis, thus minimising the overall di-
ameter of the gantry.144,145 Unlike the Riesenrad gantry, which requires a
larger shielded room, the compact eccentric gantry design reduces the swept
volume to a minimum.
Most gantries in commercial proton therapy systems are isocentric and
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Figure 2: Schematic illustration of isocentric 2- and 3-dipole gantry designs. The number
of quadrupoles required may be different to that shown. In both cases shown, spot scanning
at the patient is obtained by using fast scanning magnets placed downstream of the final
dipole. As the energy of the protons is varied the gantry magnetic field strengths must be
scaled to match the proton beam rigidity.
their size is dictated by their use of normal-conducting dipole magnets, whose
maximum field on the beam axis is restricted to around ≈1.8 T. Given that
the beam rigidity of protons at 250 MeV is 2.43 Tm, a 1.8 T field implies a
bending radius of 1.35 m; this bending radius, along with the space needed
for the beam-spreading system to cover the treatment field, sets the overall
size of proton gantries, which are typically 5 to 6 metres in radius and have
masses between 100 and 200 tons.
For carbon ions the gantry must be significantly larger. The only current
example of a carbon gantry is situated at the Heidelberg Ion Beam Therapy
Centre (HIT), and is shown in Fig. 4.122 Here the maximum carbon ion
energy used for treatment is 425 MeV/u, corresponding to a beam rigidity
of 6.57 Tm and a bending radius of 3.65 m. The use of normal-conducting
dipole technology produces a gantry ≈19 m in length and nearly ≈15 m in
diameter and with an overall mass of 600 tonnes (of which 135 tonnes is in
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Gantry Rotation
Figure 3: Schematic illustration of Riesenrad gantry.
the magnets). Despite the very large rotating mass, the positional accuracy
of the isocentre is maintained to ≈1 mm, similar to that achieved in a proton
gantry.
Another important factor in the gantry design is the method chosen to
spread the energy of the delivered particles to cover the depth range of the
treatment volume. The beam energy can be chosen to position the Bragg
peak at the distal edge of the tumour; range modulators in the treatment
nozzle are then employed to create a spread-out Bragg peak (SOBP) to match
the tumour depth profile. Alternatively, if the dose is being delivered in a
series of depth slices the energy of the particles from the source is varied.
In this latter case, the gantry magnet fields could in principle be kept fixed,
as long as there is sufficient aperture to allow the required range of energies
to be transported (for example in an FFAG gantries with a large energy
acceptance, discussed later), but typically in practice the gantry magnet field
strengths are varied to match the changing beam rigidity. The use of variable
gantry magnet fields does not usually limit the rate at which treatment may
progress from one depth layer to another in the treatment volume, as it is
usually faster than the rate at which the energy may be varied at the source
(e.g. the energy selection system of a cyclotron); typically a range step of
5 mm may be achieved in ≈100 ms using a degrader, e.g. a pair of carbon
wedges moving against each to give a varying thickness that is uniform across
the incident proton beam.
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Figure 4: The Heidelberg carbon-ion gantry, presently the only operating gantry for carbon
ion treatment. (courtesy Prof. Thomas Haberer/Heidelberg Ion Beam Therapy Centre)
6.3. Scattering Methods
The mechanism employed to distribute the dose throughout the tumour
has a significant impact on the gantry design. Coverage of the tumour by
the beam in most of today’s installations is achieved using a passive beam-
spreading technique. Passive scattering typically uses two scattering layers,
in which the first (primary) scatterer spreads the beam out laterally and a
second, about half the distance between first scatterer and patient, has a
complex variation of thickness with distance from beam axis to provide a
dose that is uniform in intensity across the treatment field width.146,65
With a double-scattering design, lateral conformation to the tumour can
be achieved using either multi-leaf collimation (MLC), analogous to that used
in x-ray radiotherapy systems, or by manufacturing a custom collimator for
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each individual patient treatment. However, the use of such collimation in
the treatment nozzle can produce an additional neutron dose for the patient.
An alternative approach to scattering is to use a set of so-called wobbler
magnets that paint the beam in a series of concentric circles, along with
collimators to establish the lateral field shape.65,147
Longitudinal conformation is achieved using the well-established tech-
nique of utilising a range modulator and compensator,148 the latter being
manufactured specifically for each patient treatment. These are typically
manufactured from a polymer, the modulator being a spinning, wedged
wheel, generating a SOBP covering the tumour longitudinally; an exam-
ple of this is shown in Fig. 5. The compensator is a fixed-energy degrader
conformed in thickness laterally across the tumour to have the distal edge of
the SOBP follow the distal edge of the tumour. This arrangement does not
provide optimal conformation to more complex target volumes, since the con-
stant depth range delivered may be larger than the tumour in some locations.
To achieve three-dimensional conformation, a range-stacking procedure must
be used; the treatment volume is divided into a series of depth slices, each
with a given outline determined by the MLC settings. By treating each depth
slice sequentially, an irregular treatment volume can be covered with higher
precision.
6.4. Spot Scanning
The alternative to the scattering or wobbler magnet approaches is spot
scanning. This is a key emerging technology that is being developed for fu-
ture proton and carbon therapy systems, as well as for retrofitting to existing
facilities. In most designs a pencil beam of a given energy and a few millime-
tres transverse size is directed to a given set of coordinates in the treatment
volume by a pair of fast-scanning deflection magnets, which cause the beam
spot to dwell on that voxel until the prescribed dose is delivered there. The
scanning magnets then move the beam to the next set of coordinates and
so forth until the beam has been painted over the full area of the treatment
volume at that desired depth. The beam energy is then changed to treat the
next layer of the treatment volume, gradually building up the layers until
the entire volume is treated. A treatment plan based on patient imaging is
used to optimise the dose over the entire treatment volume, taking account
of the dose both upstream and downstream of the Bragg peak delivered by a
particular spot. Depending upon the largest intended treatment volume the
scanning beam may need to address transverse fields up to 400 × 400 mm,
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Figure 5: Compensator (top) and range modulator (bottom) used at Clatterbridge Hos-
pital to provide longitudinal conformation of the 62 MeV protons delivered from their
cyclotron to the depth range of the tumour. The modulator wheel is 190 mm in diameter.
(courtesy Prof. Andrzej Kacperek/Clatterbridge Hospital)
although most facilities presently specify not more than 200 × 200 mm. In
any case the treatment of very wide areas may be achieved by using the
technique of field patching, in which the patient table is moved relative to
the isocentre.
The combination of pencil-beam spot scanning with a variable beam angle
from a gantry enables the technique of intensity-modulated particle therapy
(IMPT), in which several treatment fields (gantry angles) with inhomoge-
neous doses are combined to maximise the dose at the tumour and to min-
imise the dose to healthy tissue. IMPT involves active beam delivery devices
and thus requires similarly fast and accurate dosimetry; typically only a
few milliseconds can be budgeted to deliver the dose to a voxel if the total
treatment time is to be kept to a few minutes. Other advantages of spot
scanning are the elimination of patient-specific hardware - rendering patient
setup faster and less costly - and a reduction in beam loss and hence neutron
generation in the vicinity of the patient. In most current treatment nozzle
designs, the pair of fast-scanning deflection magnets are mounted after the
final dipole, as shown in Fig. 6.
An important figure of merit in pencil-beam spot scanning is the source-
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Figure 6: A schematic illustration of an idealised isocentric 3-dipole gantry which incor-
porates spot scanning magnets downstream of the final dipole. Whilst the aperture in
the final dipole may be made relatively small, there may be a significant difference in field
size (and correspondingly higher dose per unit area) at the patient surface compared to
that at the isocentre due to the finite source-to-axis distance (SAD).
to-axis distance (SAD), which is the distance from the isocentre to the ap-
parent source of the particle beam If there are no beam focusing elements
between the scanning magnets and the isocentre, the effective source location
is the point at which changes to the angle of the beam are made, i.e. the
location of the scanning magnets. Since the beam trajectories diverge from
the source, the area intercepted at the patient’s skin will be smaller than the
area at the isocentre depth, and thus a higher dose will be delivered to the
skin. Making the SAD as large as possible will therefore give the best degree
of skin sparing. There are two methods by which the SAD may be made ei-
ther very large, or even infinite. The first is to have two pairs of fast-scanning
deflection magnets mounted after the final dipole (one pair for each plane)
which could produce a parallel beam translation at the patient surface; this
either requires a large distance from the final dipole to the patient to develop
the lateral spot offset - which demands a larger gantry radius - or very tech-
nically demanding scanning magnets. Whilst this double-magnet approach
has been proposed - for example in combination with an FFAG gantry149 -
it has not yet been implemented anywhere.
The second approach is to have either one or both of the fast-scanning
deflection magnets upstream of the final dipole (one for each plane); this
scheme is shown schematically in Fig. 7. The beam optics can then be de-
signed such that the beam leaving the final dipole is translated parallel to
the zero-deflection axis as the scanning magnets alter the entrance angle
of the beam into the dipole, thereby giving an effectively infinite SAD. In
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this upstream scheme the gantry radius does not need to be increased to
include scanning; however the good field region (and therefore the magnet
pole width and the pole gap) of the final dipole must be increased to allow for
the transverse beam displacement required to produce the chosen treatment
field size, which adds significantly to its weight. In principle other beam
optical arrangements may also be used to achieve the point-to-parallel focus-
ing. The first example of a parallel scanning gantry was PSI Gantry 2,150
implemented in 1996; the final dipole is shown in Fig. 8, whilst the treatment
room is shown in Fig. 9.
Figure 7: A schematic illustration of an isocentric three dipole gantry which incorporates
spot scanning magnets upstream of the final (90 ◦) dipole. With appropriate beam optics
and entrance and exit edge angles, the betatron phase advance between the scanning mag-
nets and the isocentre may be made approximately 90 ◦, resulting in an effectively infinite
SAD. The disadvantage is that the aperture within the final dipole must be sufficient for
the intended field size, necessitating a larger good field region and hence greater mass and
excitation current requirements.
The first proton treatment gantry was constructed at the Loma Linda pro-
ton treatment centre and utilised a now-unusual “corkscrew” optics scheme,
the design providing a full 360 ◦ rotation of the beam axis around the pa-
tient.151,152 Most commercial gantry designs presently offer 360 ◦ coverage
and, if present, place the scanning magnets after the last dipole. As scan-
ning systems are usually retrofits to gantries originally fitted with passive
scattering nozzles, there is an inherently finite SAD. However, retrofitting a
scanning nozzle downstream of the final dipole does not necessitate signifi-
cant changes to the gantry beam optics.
A variety of optical schemes exist for downstream scanning, but for up-
stream scanning the “Pavlovic” design is the foremost.153 In the Pavlovic
three-dipole design the positioning of both scanning magnets upstream of
the final 90 ◦ dipole minimises the gantry radius whilst still providing an in-
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Figure 8: The gantry mechanism and final dipole of Gantry 2 at the Paul Scherrer Insti-
tute. The upstream design enables parallel scanning, which thereby simplifies treatment
planning and gives an infinite SAD which assists in skin sparing but necessitates a rather
large 45-tonne final dipole to give sufficient aperture to deliver the desired treatment field
size. (courtesy Prof. Tony Lomax/PSI)
finite SAD; the number of quadrupoles needed to match the beam from the
coupling point at the end of the beam transport to the isocentre has been
minimised to be as few as six, as shown in Fig. 10. As well as providing
parallel scanning the gantry optics design also manage the dependence of
input beam size with gantry angle, which is a more significant issue for the
usually non-symmetric beams from synchrotrons, but is solvable.117
Besides the minimisation of gantry length and radius, another method of
reducing the footprint of a treatment room is to utilise rotations of less than
360 ◦; using 180 ◦ of rotation from vertically-downward to vertically-upward
(on one side of the patient), nearly half the building footprint may be saved.
It is then of course necessary to rotate the patient table for some fields; typical
isocentric gantry and table rotation speeds are similar at ≈1 revolution per
minute, so “180 ◦” gantries may not significantly add to treatment time.
However an added problem is introduced, which is to maintain accurate
patient position registration after the table rotation. Nevertheless, the use
of restricted gantry rotation can significantly increase the patient treatment
capacity on an existing clinical site, or on the restricted space available in
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Figure 9: The Gantry 2 treatment room at the Paul Scherrer Institute. The rotating gantry
is concealed behind a sliding false wall; sufficient distance must be provided between the
end of the treatment nozzle and the patient to allow safe rotation. However, the distance
from the end of the nozzle to the patient surface should also be minimised as far as
practicable to limit scattering in the intervening air. (courtesy Prof. Tony Lomax/PSI)
the urban population centres often attractive for siting hospital facilities. A
final method which has been considered is to use obliquely-exiting beams
from the gantry, which allows for a smaller radius but restricts the range of
treatment field directions for supine patients.154
As mentioned earlier, it is also possible to directly mount the accelera-
tor source onto the gantry, as may be done with high-field superconducting
synchrocyclotrons; several examples are presently under construction and
commissioning by Mevion in the USA. Gantry sizes are similar to those for
normal-conducting gantries fed by external sources and are typically pro-
posed as either single-room or scalable clinical solutions, noting that single-
room solutions are also offered which do not mount the source on the gantry.
Another scheme is TULIP, a hybrid method in which a small (e.g. 60 MeV)
cyclotron injects protons into a combined linac and gantry. Again, this is pro-
posed as a single-room solution, but has not yet been implemented although
the accelerating structures have been developed as part of the related cyclinac
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Figure 10: Layout of the “Pavlovic” gantry with a minimised number of quadrupoles (Q1
to Q6) and three dipoles (BM45 and BM90). Sh and Sv are the horizontal and vertical
(respectively) scanning magnets. (courtesy Prof. Marius Pavlovic/STU)
approach described earlier.115
7. Future Developments
7.1. Particle Sources
The conventional accelerator source technology utilised in current proton
and carbon therapy is now rather mature; a good overview of those technol-
ogy trends has been performed by Amaldi et al.83 Here, we discuss three
particular technology developments with recent significant results.
7.1.1. Dielectric Wall Accelerators
Dielectric wall accelerators (DWA) for proton therapy are a development
from technology originally developed for high-intensity Blumlein-type lin-
ear induction accelerators to conduct flash radiography. Recent work uses
improvements in solid state switching technology to achieve direct, cavity-
less acceleration with potential gradients as high as 100 MV/m.155,156,157 If
achieved in a complete accelerator, such a gradient would allow a complete
acceleration system to 250 MeV to be only several metres in length, poten-
tially allowing it to be mounted on a gantry. Sample structures have been
demonstrated and a commercial company (CPAC) is offering a solution, with
a prototype system proposed to be ready for clinical testing around 2015.
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7.1.2. Fixed-Field Alternating Gradient Accelerators (FFAGs)
As mentioned earlier, one of the disadvantages of the classical cyclotron
is the loss of synchronism with a fixed-frequency accelerating cavity as the
accelerating protons become more relativistic; the synchrocyclotron alleviates
this problem by varying the RF frequency during bunch acceleration, with the
concomitant penalty of reduced intensity since only one bunch may be present
in the synchrocyclotron per RF frequency sweep. However, the relativistic
limit has limited the practically-achievable proton energies in either method
to ≈250 MeV.
FFAGs are an adaptation of the cyclotron with significant differences that
enable higher energies to be achieved.158,159 In both the cyclotron and the
FFAG the magnet field is fixed in time but may vary both azimuthally and
radially; the difference is that in the FFAG there is an alternating gradi-
ent in successive dipoles such that the circulating particles see strong rather
than weak focusing. The FFAG is thus akin to a strong focusing synchrotron
(albeit without varying magnetic fields) and without separated-function mag-
nets (i.e. separate dipoles and quadrupoles) in its layout.
The so-called scaling FFAG is similar to the cyclotron in having a betatron
tune that is approximately constant during acceleration, achieved by varying
the magnetic field nonlinearly with radius. The term “scaling” refers to the
fact that the orbit shape scales with energy to maintain a constant betatron
tune, so that the bunches may be kept away from damaging resonances (sim-
ilar to the procedure adopted in most particle accelerator designs). However,
like the cyclotron, the orbit radius varies greatly with energy and requires
large-aperture magnets to accommodate a significant energy range, say from
the 10s of MeV at injection to the extraction energy for treatment. The
advent of fast swept-frequency accelerating cavities around a decade ago en-
abled the first demonstration of proton FFAGs that could accelerate particles
in less than 1 ms; energies up to 150 MeV have now been demonstrated in
Japan as part of the development towards future high-power proton acceler-
ators,160 and applied at lower energy to the efficient generation of neutrons
for boron-neutron capture therapy.161
The non-scaling FFAG uses strong non-linear magnets to allow accelera-
tion over a large energy range whilst retaining small-aperture magnets, and
has recently been demonstrated experimentally for electrons.162 Although
the magnets may be made smaller, the lack of orbit scaling with energy in-
herently gives rise to the crossing of resonances during acceleration; it has
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been demonstrated that this may be successfully carried out if magnet toler-
ances are sufficiently well controlled, but a demonstration of the non-scaling
principle with protons has yet to be carried out.
Two detailed design studies have been carried out to examine the use of
FFAGs for medical therapy, although others have also been performed.163,164
The first - RACCAM - was a design study for a multi-room treatment centre
based on a 180 MeV normal-conducting scaling FFAG.165 Energy variation
in 250 keV steps (one step per second) is planned at five possible extrac-
tion points, each potentially equipped with a patient gantry. However, the
scanning speed is envisaged to be significantly better than that obtainable
with present-day synchrotrons. The second design study - PAMELA89 - pro-
posed a two-ring non-scaling FFAG delivering both protons up to 250 MeV
and carbon ions up to 400 MeV/u; a novel superconducting magnet triplet
design was developed during the course of the study to allow nonlinear cor-
rection of the magnetic lattice.166,167 The proposed advantage of PAMELA
is the possibility of having variable energy pulses delivered at rates as high
as 1 kHz; the difficulty resides in the need for rather complex superconduct-
ing magnets and a very fast pulsed extraction system to produce the rapid
energy variation. Whilst there is potential commercial interest in FFAGs,
there are at present no planned clinical centres that utilise them.
7.1.3. Laser Proton Acceleration
Protons and other ions may be accelerated using laser pulses in several
ways; recent reviews have been given by Daido et al.,168 Norreys169 and Mac-
chi et al.170 One recent advance has been the demonstration of so-called
target normal sheath acceleration (TNSA), whereby protons are accelerated
from the rear of a thin target illuminated by a strong laser pulse due to the
electron pressure within the target.171 Acceleration of protons and ions has
been demonstrated up to 10s of MeV with reasonable beam quality and en-
ergy spread;168,172,173 however, whilst scaling to clinically-relevant energies
up to 250 MeV has been modelled there has not yet been demonstration to
those energies. A number of research groups are engaged in achieving this
goal, and are considering how to deliver the pulse repetition rates required
for clinical application174 and to utilise the resulting protons.175 One av-
enue is the use of radiation-pressure (“light sail”) acceleration,176 in which
the incident photons themselves impart momentum to the accelerated ions.
Whilst the use of laser technology is very promising, it is likely that it will be
a few years before clinical experiments are carried out and there are no com-
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mercial companies with plans to offer laser-accelerated protons for clinical
use. One possible advantage of laser-based acceleration, like other compact
proton sources, is the ability to mount the entire particle source onto a deliv-
ery gantry. Efficient collection and focusing of these laser-derived particles
requires a compact delivery system, based on either conventional magnets
(either quadrupolar or solenoidal)177,178 or on Gabor lenses.179,180
7.2. Gantries
Similar to accelerator sources, delivery gantries have seen a great deal
of development; in contrast though, gantry design has evolved towards one
of two canonical design approaches, either an isocentric gantry delivering
externally-generated protons, or a gantry-mounted source delivering protons
direct to the patient. Here, we discuss two approaches for making isocentric
gantries more compact.
7.2.1. Superconducting Magnets
All three of the driving forces in gantry development, namely:
• Reducing their size and cost;
• Increasing the beam energy for the same size;
• Utilising ions heavier than protons;
require increased magnetic field strength (both for bending and focusing)
integrated over the beam path. Of course, the gantry size is a significant cost
driver of the whole treatment facility; a gantry treatment room is comparable
in size or larger than most accelerator sources. Also, gantries for carbon ion
therapy require larger magnets and in order to have a wider adoption of
carbon-ion therapy it will be necessary to reduce the size and mass of the
magnets. One method to achieve this is to adopt superconducting technology.
The advantages of superconducting magnets are that they can support
a much larger magnetic field than a normal-conducting magnet and because
there are almost no resistive losses in the magnet circuit they cost less to
power. Widely used in particle accelerators used for research for many years,
they consist of either iron-cored or core-less magnets incorporating supercon-
ducting coils which are typically cooled to less than 4 K using liquid helium;
the use of high-temperature superconductors in this application has not yet
been widely demonstrated.
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Several groups - some with commercial involvement - have proposed core-
less curved superconducting dipoles which produce fields up to 3.3 T or
more.181 Core-less superconducting dipole magnets have been prototyped to
some extent, but suitable magnetic field distribution and quality have not
been demonstrated experimentally for all the magnet types required in a prac-
tical gantry. Superconducting gantry designs are underway at ETOILE182
and NIRS;183 for example, the 3.3 T field proposed for ETOILE signifi-
cantly reduces the dipole bend radius for 425 MeV/u carbon ions to around
2 m, resulting in gantry dimensions (13.5 m long by 4 m radius) and mass
(210 tonnes) which are comparable to normal-conducting gantries for pro-
tons. An example of a superconducting gantry design for NIRS is shown in
Fig. 11 and Fig. 12. The NIRS design envisages their synchrotron producing
carbon ions between 430 MeV/u and 56 MeV/u in 200 steps, corresponding
to a 1 mm to 2 mm range in water.184 Ridge filters are then used to produce
a mini-SOBP of between 1 to 3 mm. Similarly, the superconducting magnets
will change their field to match the beam energy within 200 ms. The results
of tests of the prototype magnets and cryostats are promising.185
Although there are savings in the electrical power circuits that supply su-
perconducting magnets coils when compared to normal conducting coils, su-
perconducting magnets are more problematic to use than normal-conducting
ones as they must be cooled to a few kelvin. There is also the higher capi-
tal cost associated with the magnets themselves and for their cooling system.
The use of conventional liquid helium-filled cryostats is probably not possible
as liquid movement during rotation would lead to potential quenching, and
so the approaches described above typically plan to use cryocoolers. These
are cryogen-free heat pumps186 and so allow rotation of a magnet on a gantry,
but they typically have a more limited capacity than cryogenic-liquid cooling
systems. The NIRS design envisages a pre-cooling procedure using liquid ni-
trogen to reduce the temperature to ≈70 K, prior to the use of cryocoolers to
further cool the magnets to 4 K. This will reduce the total time to get from
room temperature to 4 K from about a month to six or seven days. A further
complication is that superconducting magnets are prone to quenching when
new (and until a period of training has been undertaken) and also when re-
quired to change field rapidly. Tests at NIRS have shown that quenches can
be recovered from immediately; although realistically it may take up to two
hours. It is not yet clear how quenching would be managed if it happened
part-way through a treatment fraction. That being said, significant progress
has been made in Japan toward the realisation of a superconducting gantry
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and it is likely that one will be operational soon.
7.2.2. FFAG Gantries
An alternative approach to conventional beam optics using supercon-
ducting magnets is the use of fixed-field, alternating-gradient (FFAG) optics
which in principle give very large energy acceptance with a small magnet
aperture. FFAGs gantries make use of combined-function dipole magnets
with large focusing gradients that alternate in sign along the beam path.
The large gradients, and the use of non-scaling beam optics design, min-
imise the dipole-generated beam dispersion and thereby restrict the aperture
required for a given energy range; energy scanning may then be carried out
without varying the magnetic field of the gantry magnets. Thus some designs
propose the use of permanent magnets to reduce the weight. FFAG gantries
may also utilise superconducting or conventional normal-conducting magnet
technology, and a number of optical and technological solutions have been
proposed.187,164,149 It is proposed in particular that FFAG gantries for car-
bon ion transport may be significantly smaller and lighter than other designs.
An example layout of a superconducting FFAG gantry is shown in Fig. 13. In
treatment situations where the energy range that is required is larger than is
available from the FFAG gantry optics, it is proposed to use a small number
of magnetic field settings to cover the depth range. Although a number of
innovations have been proposed, including the provision of parallel scanning
mentioned previously, an FFAG gantry has not yet been demonstrated.
8. Summary
Following a long period of experimentation before becoming fully ac-
cepted, proton and other light ion beam therapies are now well-established
clinical techniques. Whilst IMRT may give excellent dose conformation to
the tumour, protons provide the possibility of significantly reducing the dose
to surrounding tissues and organs at risk. For the treatment of particular
types of cancer this advantage outweighs the additional technology costs,
particularly in paediatric treatments where the induction of secondary tu-
mours or other side-effects can have particularly deleterious impacts on the
patient in later life.
In recent years - and particularly in the last decade - proton treatment
technology has advanced greatly, and the advent of scanned beams and IMPT
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have significantly improved the capability of proton treatment. Mature tech-
nology solutions are now available in the marketplace, but there remain op-
portunities for improvement, either to further improve clinical capability or
to reduce cost; both of these aims are important to realise the full potential
of proton and ion therapy. There is already a well-established pattern in this
field, in which accelerator technology research from state-funded research
(e.g. at national laboratories) has been successfully transferred and devel-
oped to clinical practice by commercial organisations. Ion beam therapy has
benefitted from the forward-looking nature of many companies in the field
and from the investment they have been brought to create new products.
A number of novel accelerator technologies are being developed that as-
pire to provide greater capability or reduced cost, but will have yet to show
their advantages in comparison to existing offerings. At the accelerator source
end, we note the steadily increasing use of superconducting technology for
proton acceleration, which has aimed to reduce cost and size, enable mobile
sources, or enable higher energies to be achieved. We also note dielectric wall
accelerators and non-scaling FFAGs as being disruptive technologies: they
promise significantly improved capabilities (DWAs offering much reduced size
and ns-FFAGs promising more rapidly variable energy), but neither have yet
been demonstrated in a clinical setting.
Carbon-ion therapy has become the de-facto standard for (non-proton)
ion therapy and makes inherently greater demands on the technology com-
pared to protons. As a result, it has pushed the development of higher-
gradient acceleration and higher magnetic fields for beam delivery. Several
groups have been involved in developing superconducting magnets suitable
for gantries and we believe this is a key technology for the near future.
The strong focusing and compact magnet arrangements available in FFAG
gantries could also offer potential benefits for scanning and to obtain smaller
size, but given the more complex beam optics it will be necessary to construct
a prototype.
It is not only carbon ions that may benefit from the use of higher fields or
other methods to achieve smaller gantry sizes than the present successful but
conservative designs. In proton therapy, there is a desire to reduce the gantry
size to enable a larger number of treatment rooms on a given site or to enable
higher energies to be transported, e.g. to enable the use of proton computed
tomography. Given the typically urban location of treatment centres this
desire will persist. We note here the trend towards opting for reduced gantry
angle range (≈ 180 ◦ instead of ≈ 360 ◦) for which there is a tradeoff between
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capital cost and throughput. Throughput remains a key indirect cost driver
and the possible reliability and throughput advantages of gantry-mounted
sources has only begun to be addressed by the initial example developed by
Mevion.
In conclusion, we believe that despite the great advances in ion therapy
technology in the last few years, there remain significant opportunities. In
the near-term we believe superconducting technology will play an increas-
ingly important role, particularly in beam gantries. Further on, new com-
pact accelerator sources - possibly including laser-based acceleration - offer
the ability to provide gantry-mounted solutions if sufficient gradient can be
achieved; these could potentially offer throughput or cost advantages, but
have to compete against the established mature solutions based on conven-
tional accelerator technology.
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Figure 11: Three-dimensional image of the NIRS superconducting rotating gantry for
heavy-ion therapy. (courtesy Dr. Yoshiyuki Iwata/NIRS)
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ΔΔ
Figure 12: Layout of the NIRS superconducting rotating gantry. The gantry consists of
ten superconducting magnets (BM1-10), a pair of scanning magnets (SCM-X and SCM-
Y) and three pairs of beam profile-monitor and steering magnets (STR1-3 and PRN1-3).
(courtesy Dr. Yoshiyuki Iwata/NIRS)
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 Figure 13: Schematic layout of proposed superconducting FFAG isocentric gantry for
carbon therapy,149 utilising triplet magnets in which the defocusing dipole has a maximum
field of 5.58 T and a gradient of of -93 T/m. This design allows a carbon gantry in principle
to be as small as existing proton gantries . (courtesy Dr. Dejan Trbojevic/Brookhaven
National Laboratory)
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